RSV vaccine News

Moderna's Shares Dive 19%: A Closer Look at the 2025 Revenue Forecast Adjustment

Moderna Inc. revises its 2025 revenue forecast downwards to between $1.5 billion and $2.5 billion, citing a slow RSV vaccine rollout and decreased COVID-19 vaccine demand, leading ...